UNSPSC 51453004: Piperazine calcium edetate

This classification denotes an antihelminthic agent "C10H12N2O8.C4H10N2.2""H+"".Ca", a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L4QEN8344Z, chemically known as calciate(2-), ((n,n'-1,2-ethanediylbis(n-(carboxymethyl)glycinato))(4-)-n,n',o,o',on,on')-, (oc-6-21)-, dihydrogen, compd. with piperazine (1:1), but more generally known as piperazine calcium edetate, which bears US NIH Compound Identifier 23724991.

European Medicines Agency schedules Piperazine calcium edetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09869MIG. Most nations, for tariff and trade purposes, schedule piperazine calcium edetate under HS 29335990 and SITC 51576. SMILES: As of Q4 2014, PIPERAZINE CALCIUM EDETATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51453004 Piperazine calcium edetate is a Commodity code covering specialized pharmaceutical compounds and chemical agents used in medical and public health applications. Recent state and local solicitations tagged under this code show procurement of naloxone (an opioid-overdose reversal agent) and safe drug deactivation systems rather than piperazine calcium edetate itself, indicating a mismatch between the code's nominal scope and the work actually being bought. The issuing bodies are county health departments and state public health agencies procuring these pharmaceutical supplies through competitive bidding and cooperative purchasing vehicles. Seminole County, Florida posted an IFB on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Illinois Department of Public Health awarded a $2.99 million pharmaceutical piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for supply of two pharmaceutical products under an Invitation for Bid, though that contract covered doxycycline and ciprofloxacin rather than the code's stated product.

The code shows limited recent activity directly aligned with its nominal scope. Geographic presence spans Florida and Illinois based on the recent opportunities. No set-asides or preference programs are documented in the recent solicitations, and no clear pattern of repeat buyers emerges from the sparse posting record. The mismatch between the code label and the actual pharmaceutical products being solicited suggests this code may not be the primary taxonomy entry for state and local naloxone and drug-deactivation procurement, or that tagging practice varies across jurisdictions.